Table 1.
Patient characteristics
| Entire cohort n=1158 | Colorectal cancer n=991 | Endometrial cancer n=167 | |
| Age | |||
| Mean±SD | 62.6±10.3 | 62.4±10.3 | 63.4±10.5 |
| Median | 64.3 | 64.4 | 64.2 |
| Min-Max | 21–87 | 21–82 | 35–87 |
| Gender | |||
| Female | 614 (53%) | 447 (45.1%) | 167 (100%) |
| Male | 544 (47%) | 544 (54.9%) | |
| Tumour location | – | – | |
| Right | 308 (31.5%) | ||
| Left | 392 (40.1%) | ||
| Rectum | 278 (28.4%) | ||
| Missing | 13 | ||
| Primary tumour (T) | |||
| T1 | 133 (11.9%) | 4 (0.4%) | 129 (80.1%) |
| T2 | 91 (8.1%) | 79 (8.3%) | 12 (7.5%) |
| T3 | 826 (73.9%) | 806 (84.2%) | 20 (12.4%) |
| T4 | 68 (6.1%) | 68 (7.1%) | 0 (0%) |
| Missing | 40 | 34 | 6 |
| Regional lymph nodes (N) | |||
| N0 | 533 (48.2%) | 408 (42.3%) | 125 (88.7%) |
| N1 | 382 (34.6%) | 370 (38.4%) | 12 (8.5%) |
| N2 | 190 (17.2%) | 186 (19.3%) | 4 (2.8%) |
| Missing | 53 | 27 | 26 |
| Stage | |||
| I | 128 (11.2%) | 8 (0.8%) | 120 (74.5%) |
| II | 415 (36.2%) | 405 (41.2%) | 10 (6.2%) |
| III | 602 (52.6%) | 571 (58%) | 31 (19.3%) |
| Missing | 13 | 7 | 6 |
| Grade | |||
| 1 | 125 (11.1%) | 77 (8%) | 48 (29.1%) |
| 2 | 800 (70.8%) | 725 (75.1%) | 75 (45.5%) |
| 3 | 205 (18.1%) | 163 (16.9%) | 42 (25.4%) |
| Missing | 28 | 26 | 2 |
| Mucinous component | – | – | |
| No | 453 (55.8%) | ||
| Yes | 360 (44.2%) | ||
| Missing | 178 | ||
| Perineural invasion | – | – | |
| No | 716 (85.6%) | ||
| Yes | 121 (14.4%) | ||
| Missing | 154 | ||
| Lymphatic vessel invasion | – | – | |
| No | 637 (75.7%) | ||
| Yes | 205 (24.3%) | ||
| Missing | 149 | ||
| Blood vessel invasion | – | – | |
| No | 721 (85%) | ||
| Yes | 128 (15%) | ||
| Missing | 142 | ||
| PNI/LVI | – | – | |
| No | 590 (69.4%) | ||
| Yes | 260 (30.6%) | ||
| Missing | 141 | ||
| Chemotherapy | – | – | |
| Yes | 991 (100%) | 20 (12%) | |
| No | 147 (88%) | ||
| Chemotherapy regimen | |||
| 5FU/capecitabine | 158 (16.6%) | ||
| FOLFOX | 271 (28.5%) | ||
| CapeOX | 372 (39.1%) | ||
| FOLFIRI | 118 (12.4%) | ||
| Other | 32 (3.4%) | ||
| Missing | 40 | ||
| Radiation therapy | |||
| No | 721 (67.3%) | 657 (72.7%) | 64 (38.3%) |
| Yes | 350 (32.7%) | 247 (27.3%) | 103 (61.7%) |
| Missing | 87 | 87 | 0 |
CapeOX, capecitabine/oxaliplatin; FOLFIRI, 5-FU/ leucovorin/irinotecan; FOLFOX, 5-FU/leucovorin/oxaliplatin; 5FU, 5-fluoruracil; LVI, lymphovascular invasion; N, number; PNI, perineural invasion.